FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808048547> ?p ?o ?g. }

• W2808048547 endingPage "170" @default.
• W2808048547 startingPage "165" @default.
• W2808048547 abstract "Objectives To evaluate the local control (LC) and long term adverse effects in a series of patients with lung metastases who received 30 Gy in single dose with stereotactic technique. Materials and Methods Between December 2008 and April 2016, a total of 166 lung metastases in 129 patients affected by oligometastatic disease were treated at our Institution with stereotactic body radiotherapy (SBRT). Mainly, the primary tumors were non small-cell lung cancer and colorectal cancer (45.2% and 28.8%, respectively). Prognostic factors were also assessed. Results The median follow-up was 38 months. Local progression occurred in 24 (14.4%) lesions in 21 patients. Intra-thoracic progression (new lung lesions or thoracic lymph node metastases) occurred in 59 (45.7%) patients. Forty-five (34.8%) patients had distant progression after a median time of 14 months. The 3- and 5-years local relapse-free survival (LPFS) were 80.1% and 79.2% (median not reached), respectively. One-hundred forty-eight patients were evaluated for late toxicity (follow-up >6 months): 51 (34.4%) patients had grade ≤2 fibrosis, 11 (7.4%) patients experienced grade 3 fibrosis. Two (1.3%) cases of rib fracture occurred. One case of toxic death (grade 5) has been reported. Median OS was 39 months. At the univariate analysis, lesion diameter ≤18 mm correlated significantly with a longer LPFS (p = 0.001). At the multivariate analysis, lesion diameter <18 mm was predictive for longer LPFS (p = 0.006). Also, oligometastases from primary colorectal cancer was a significant predictive factor for worse LPFS (p = 0.041) and progression-free survival (p = 0.04). Conclusions To our knowledge, the current study represents the largest series on the use of SBRT 30 Gy single dose for lung metastases. Our results confirm the effectiveness and safety of this schedule administered in selected oligometastatic patients. Further prospective series could better validate these results." @default.
• W2808048547 created "2018-06-21" @default.
• W2808048547 creator A5033043182 @default.
• W2808048547 creator A5035717109 @default.
• W2808048547 creator A5036804510 @default.
• W2808048547 creator A5043003981 @default.
• W2808048547 creator A5048429301 @default.
• W2808048547 creator A5049884922 @default.
• W2808048547 creator A5068601418 @default.
• W2808048547 creator A5069369968 @default.
• W2808048547 creator A5080572439 @default.
• W2808048547 creator A5087162477 @default.
• W2808048547 creator A5088836572 @default.
• W2808048547 creator A5091286114 @default.
• W2808048547 date "2018-08-01" @default.
• W2808048547 modified "2023-10-17" @default.
• W2808048547 title "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" @default.
• W2808048547 cites W1648328586 @default.
• W2808048547 cites W1973594991 @default.
• W2808048547 cites W1984747135 @default.
• W2808048547 cites W2001438671 @default.
• W2808048547 cites W2032060090 @default.
• W2808048547 cites W2034546784 @default.
• W2808048547 cites W2037407820 @default.
• W2808048547 cites W2041547867 @default.
• W2808048547 cites W2046067887 @default.
• W2808048547 cites W2052345941 @default.
• W2808048547 cites W2076990946 @default.
• W2808048547 cites W2105572101 @default.
• W2808048547 cites W2115646671 @default.
• W2808048547 cites W2131441386 @default.
• W2808048547 cites W2154119889 @default.
• W2808048547 cites W2166459387 @default.
• W2808048547 cites W2171123343 @default.
• W2808048547 cites W2301303331 @default.
• W2808048547 cites W2536769127 @default.
• W2808048547 doi "https://doi.org/10.1016/j.lungcan.2018.06.018" @default.
• W2808048547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30032826" @default.
• W2808048547 hasPublicationYear "2018" @default.
• W2808048547 type Work @default.
• W2808048547 sameAs 2808048547 @default.
• W2808048547 citedByCount "29" @default.
• W2808048547 countsByYear W28080485472019 @default.
• W2808048547 countsByYear W28080485472020 @default.
• W2808048547 countsByYear W28080485472021 @default.
• W2808048547 countsByYear W28080485472022 @default.
• W2808048547 countsByYear W28080485472023 @default.
• W2808048547 crossrefType "journal-article" @default.
• W2808048547 hasAuthorship W2808048547A5033043182 @default.
• W2808048547 hasAuthorship W2808048547A5035717109 @default.
• W2808048547 hasAuthorship W2808048547A5036804510 @default.
• W2808048547 hasAuthorship W2808048547A5043003981 @default.
• W2808048547 hasAuthorship W2808048547A5048429301 @default.
• W2808048547 hasAuthorship W2808048547A5049884922 @default.
• W2808048547 hasAuthorship W2808048547A5068601418 @default.
• W2808048547 hasAuthorship W2808048547A5069369968 @default.
• W2808048547 hasAuthorship W2808048547A5080572439 @default.
• W2808048547 hasAuthorship W2808048547A5087162477 @default.
• W2808048547 hasAuthorship W2808048547A5088836572 @default.
• W2808048547 hasAuthorship W2808048547A5091286114 @default.
• W2808048547 hasConcept C121608353 @default.
• W2808048547 hasConcept C126322002 @default.
• W2808048547 hasConcept C126838900 @default.
• W2808048547 hasConcept C141071460 @default.
• W2808048547 hasConcept C144301174 @default.
• W2808048547 hasConcept C197934379 @default.
• W2808048547 hasConcept C2776256026 @default.
• W2808048547 hasConcept C2776694085 @default.
• W2808048547 hasConcept C2777714996 @default.
• W2808048547 hasConcept C2778822529 @default.
• W2808048547 hasConcept C2780387249 @default.
• W2808048547 hasConcept C2780849966 @default.
• W2808048547 hasConcept C2781156865 @default.
• W2808048547 hasConcept C38180746 @default.
• W2808048547 hasConcept C509974204 @default.
• W2808048547 hasConcept C526805850 @default.
• W2808048547 hasConcept C71924100 @default.
• W2808048547 hasConceptScore W2808048547C121608353 @default.
• W2808048547 hasConceptScore W2808048547C126322002 @default.
• W2808048547 hasConceptScore W2808048547C126838900 @default.
• W2808048547 hasConceptScore W2808048547C141071460 @default.
• W2808048547 hasConceptScore W2808048547C144301174 @default.
• W2808048547 hasConceptScore W2808048547C197934379 @default.
• W2808048547 hasConceptScore W2808048547C2776256026 @default.
• W2808048547 hasConceptScore W2808048547C2776694085 @default.
• W2808048547 hasConceptScore W2808048547C2777714996 @default.
• W2808048547 hasConceptScore W2808048547C2778822529 @default.
• W2808048547 hasConceptScore W2808048547C2780387249 @default.
• W2808048547 hasConceptScore W2808048547C2780849966 @default.
• W2808048547 hasConceptScore W2808048547C2781156865 @default.
• W2808048547 hasConceptScore W2808048547C38180746 @default.
• W2808048547 hasConceptScore W2808048547C509974204 @default.
• W2808048547 hasConceptScore W2808048547C526805850 @default.
• W2808048547 hasConceptScore W2808048547C71924100 @default.
• W2808048547 hasLocation W28080485471 @default.
• W2808048547 hasOpenAccess W2808048547 @default.
• W2808048547 hasPrimaryLocation W28080485471 @default.
• W2808048547 hasRelatedWork W1490990766 @default.

• next